A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Xin Li, MD
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
27 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Peking University Cancer Hospital
Beijing, Beijing Municipality, China
- Xinqiao Hospital of Army Medical University
Chongqing, Chongqing Municipality, China
Zhi Xu - Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China
Jing Zhang - the First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Jingxun Wu - Dongguan People'S Hospital
Dongguan, Guangdong, China
Guanming Jiang - Guangzhou Medical University First Affiliated Hospital
Guangzhou, Guangdong, China
Chengzhi Zhou - Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
Li Zhang - Guilin Medical University First Affiliated Hospital
Guilin, Guangxi, China
Yanyi Zhao - Guangxi Medical University Affiliated Tumor Hospital
Nanning, Guangxi, China
Qitao YuYun Zhao - Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Qingwei MengYan Yu - Henan Cancer Hospital
Zhengzhou, Henan, China
Qiming Wang - the First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
- Xiangyang Central Hospital
Xiangyang, Hubei, China
Tienan Yi - Hunan Cancer Hospital
Changsha, Hunan, China
Bolin ChenXingxiang Pu - Jiangsu Province Hospital
Nanjing, Jiangsu, China
Wangjian Zha - Jiangxi Cancer Hospital
Nanchang, Jiangxi, China
Zhentian Liu - Jilin Cancer Hospital
Changchun, Jilin, China
Haifeng Liu - Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
Wei Zheng - Shandong Cancer Hospital
Jinan, Shandong, China
Haiyong WangYan Zhang - Shanxi Cancer Hospital
Taiyuan, Shanxi, China
Wei Guo - the First Affiliated Hospital of Xi'An Jiao Tong University
Xi’an, Shanxi, China
Yu Yao - Sichuan Cancer Hospital & Institute
Chengdu, Sichuan, China
Wenxiu Yao - West China Hospital, Sichuan University
Chengdu, Sichuan, China
Guowei Che - Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China
Liuchun Wang - Xinjiang Medical University Affiliated Tumor Hospital
Ürümqi, Xinjiang Uygur Autonomous Region, China
- Yunnan Cancer Hospital
Kunming, Yunnan, China
Runxiang Yang - Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Xinmin Yu
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2026
- Primary completion
- 31 Dec 2028
- Completion
- 31 Dec 2029
- Last update posted
- 3 Jun 2026
- Registered enrollment
- 150
- Registry id
- NCT07622186
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.